Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026
- Financial position as of June 30, 2026 and a business update announced August 6, 2026
- Detailed results and operating developments available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $18.0M, or $0.19 per share, versus $8.0M loss, reflecting sharply higher development spending
- Research and development expense $16.0M, up from $7.9M, as enrollment advances across Phase 3 PTCL and Phase 2 atopic dermatitis trials
- Cash, equivalents and marketable securities $215.2M, including $189.4M financing proceeds, supporting operations into 2Q28
- Soquelitinib Phase 3 PTCL trial targets 150 patients, with progression-free survival as the primary endpoint
- Corvus invested $5.0M in Angel Pharma’s $13.5M financing, supporting atopic dermatitis and planned asthma development in China
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.